Mathew, AnujaTerajima, MasanoriWest, KimGreen, SharoneRothman, Alan L.Ennis, Francis A.Kennedy, Jeffrey S.2022-08-232022-08-232005-02-092008-11-10<p>J Immunol. 2005 Feb 15;174(4):2212-9.</p>0022-1767 (Print)10.4049/jimmunol.174.4.221215699154https://hdl.handle.net/20.500.14038/34159Murine T cell epitopes against vaccinia virus (VV) have not been characterized to date in part due to the large and complex genome of VV. We have identified and characterized two CD8+ T cell epitopes on the A47L (modified VV Ankara strain (MVA)-029) and J6R (MVA-043) proteins of VV that are Db and Kb restricted, respectively. Following i.p. immunization with VV New York City Board of Health (NYCBH) strain, MVA-029 peptide-stimulated splenocytes secreted IFN-gamma from 7 days to 7 mo postimmunization, and virus-stimulated effectors were also able to lyse MVA-029-pulsed target cells at the same time points. In contrast, MVA-043 peptide-stimulated splenocytes secreted very low levels of IFN-gamma only at day 7 but maintained the ability to lyse target cells up to 2 mo postimmunization. Both MVA-029 and MVA-043 peptide-stimulated lymph node cells degranulated similarly as assessed by Ag-induced CD107 expression. T cell responses to whole-virus stimulation remained robust and steady during the acute and memory T cell response to VV. Identification of T cell epitopes on VV will enable further studies to increase our understanding of the role of CD8+ T cells in VV infection and assist in the design of new protective strategies.en-USJournal Articlehttps://escholarship.umassmed.edu/gsbs_sp/819663947gsbs_sp/819